Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

All eligible patients will receive craniocerebral radiotherapy in combination with Almonertinib. Here are two types of craniocerebral radiotherapy: 1. SRS or SRT is recommended for patients with ≤4 intracranial metastases and the maximum lesion ≤4cm. 24-15 Gy\*1F was recommended if use SRS. 9-12 Gy\*3F or 6Gy×5F was recommended if use SRT. 2. For \>4 intracranial metastases, or the maximum lesion\>4cm, whole-brain radiotherapy (WBRT) of 30Gy/10F was recommended, and then the large residual lesions will be treated with a local dose (≤DT 45Gy/15F). Hippocampal protection is highly recommended.